Biography
Dr Catherine Cafferkey is a Consultant Medical Oncologist specialising in breast cancer. She has been a Consultant at St George’s Hospital NHS Foundation Trust in London since 2019, where she works within the Breast and Acute Oncology.
She completed her specialist registrar training in Medical Oncology at The Royal Marsden Hospital, London, following medical training at Guy’s, King’s and St Thomas’ School of Medicine, University of London.
Dr Cafferkey holds a Diploma in Oncology from the Institute of Cancer Research and is a Member of the Royal College of Physicians. She is currently Principal Investigator for the TROPION-02 Phase III clinical trial and regularly contributes to national meetings, including presenting as part of the breast multidisciplinary team at the UKIO conference in 2022, 2023 and 2024.
She is the Medical Oncology Training Unit Lead for GSTT at St George’s Hospital and is actively involved in teaching medical students, junior doctors and oncology trainees. She has extensive experience in bedside and clinic-based teaching, practical procedural training, and has completed advanced communication and teaching courses at King’s College London.
Other posts held
St George’s University Hospitals NHS Trust
GMC: 6078675
Publications
Maintenance durvalumab after first line platinum based chemotherapy in advanced OG Adenocarcinoma: Results from the PLATFORM trial. Journal of Clinical Oncology May 2021 Fong C, Patel B, Peckitt C, Cafferkey C et al May 2021
Evaluating maintenance therapies in advanced OG adenocarcinoma: Interim analysis
results from the PLATFORM study. Cunningham D, Fong C, Cafferkey C et al
Journal of Clinical Oncology Feb 2020
Treatment of relapsed OGA after perioperative chemotherapy and surgery Davids Butler
C,Cafferkey C Annals of Oncology July 2019
Detecting and Tracking Circulating Tumour DNA copy number Profiles during First Line
chemotherapy in OGA cancer. Davidson M, Barber L, Gerlinger M, Cafferkey C et a
Cancers May 2019
Genomic loss of heterozygosity and survival in the REAL3 Trial. Cafferkey C, Smyth E, Chau I et al accepted for publication in Oncotarget Oct 2018.